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Abstract This paper makes the case for implementing an
internal governance framework for sharing materials and data
in stem cell research consortia. A governance framework can
facilitate a transparent and accountable system while building
trust among partner institutions. However, avoiding excessive
bureaucracy is essential. The development and implementa-
tion of a governance framework for materials and data access
in the Stem cells for Biological Assays of Novel drugs and
prediCtive toxiCology (StemBANCC) consortium is present-
ed as a practical example. The StemBANCCproject is a multi-
partner European research consortium, which aims to build a
resource of 1,500 well characterised induced pluripotent stem
cell (iPSC) lines for in vitro disease modelling and toxicology
studies. The project governance framework was developed in
two stages. A small working group identified key components
of a framework and translated the project legal agreements
into a draft policy document. The second phase allowed input
from all consortium partners to shape the iterative develop-
ment of a final policy document that could be agreed by all
parties. Careful time management strategies were needed to
manage the duration of this component. This part of the pro-
cess also served as an exploratory space where different op-
tions could be proposed, potential gaps in planning identified,
and project co-ordination activities specified.
Keywords Stemcell research (SCR) .Governance .Materials
and data access . Induced pluripotent stem cells (iPSCs) .
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Introduction
Over the past decade there has been a significant rise in the use
of public-private funding agreements to bring together aca-
demic and industrial organisations in large consortia. [1]
One factor driving the creation of these research consortia is
the increasing volume and complexity of datasets involved in
addressing major challenges in the life-sciences. [2] Such vol-
umes of data are often beyond the capacity of any one group
or institution to process efficiently. Multi-sector collaborations
are needed to leverage the infrastructure, multi-disciplinary
expertise and other resources required to address these chal-
lenges. [3] Rising healthcare costs and declining returns from
traditional pharmaceutical industry R&D are also driving sup-
port for academic-industry consortia dedicated to
reinvigorating drug discovery through the application of novel
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technologies such as genomics and stem cell science. [3–5]
Examples include the Québec Consortium for DrugDiscovery
(CQDM) in Canada and the Innovative Medicine’s Initiative
[6] (IMI) in Europe. The need for collaborative sharing of
biological samples and data on a large scale is also a key part
of Europe’s agenda on addressing rare disease (RD) [7].
Sharing data, especially sensitive ‘individual level’ medi-
cal, personal, and biological data, requires appropriate gover-
nance. [8, 9] Governance incorporates the full range of formal
and informal options for organising, co-ordinating and con-
trolling activities and is not limited to the legal requirements of
formal regulation. Regulatory requirements remain mandatory
and must be met, but the legal requirements for SCR are ad-
equately addressed elsewhere [10] and the focus here is on the
less formal mechanisms of governance that can be applied to
the internal organisation of a collaborative consortium. Hav-
ing an internal governance system for data sharing between
consortium partners can facilitate transparency and account-
ability, foster trust between institutions, and augment project
organisation and co-ordination capabilities. However, gover-
nance systems also need to avoid unintentionally creating new
obstacles to data sharing such as excessive bureaucracy and
overly elaborate access procedures. A number of recent pub-
lications have discussed the challenges and benefits of
implementing governance structures for data sharing within
contemporary large consortia, but these focus predominantly
on sharing of genomic data [8, 11, 12].
Although access to materials and data has been identified
as especially critical to stem cell science [13] it has been sug-
gested that the stem cell community has been somewhat
slower to respond to the changing frameworks of biomedical
innovation and translation. [4] Unlike genomic and other med-
ical data, which can readily be digitised and shared through
Information Communication Technology (ICT) platforms,
stem cell research (SCR) involves material biological objects,
which can only be shared through physical transportation be-
tween locations and partners. SCR therefore at least potential-
ly raises different and unique challenges for sharing material
and data amongst large academic industry research consortia.
One obvious issue is that novel platforms for collaborative
data sharing such as Datashield [2] have not been designed
with SCR inmind and may be less relevant for SCR consortia.
This reflects a more general sense that data and materials
sharing in SCR consortia has not, to date, received adequate
attention, especially compared to similar examinations of
genomics-based consortia.
In order to redress this situation, this paper describes the
development and implementation of an intra-consortium gov-
ernance mechanism for sharing materials and data in a con-
temporary IMI research consortium, Stem cells for Biological
Assays of Novel drugs and prediCtive toxiCology
(StemBANCC). This case selection provides an example of
how abstract challenges of materials and data sharing can be
addressed in practice, in a working SCR consortium. While
the specifics of many of the challenges encountered in the
StemBANCC consortium may be particular to this project,
the nature of these challenges and the methods for resolving
them can stand as a useful resource for current and future SCR
consortia.
To provide appropriate context for this discussion it is first
necessary to briefly review the purpose and components of a
governance system itself and to provide some additional de-
tails on the nature of the StemBANCC consortium. The great-
er part of this paper will then describe the design and imple-
mentation of the StemBANCC Biorepository Materials and
Data Access policy and the insights that can be drawn from
this experience for future SCR consortia.
The StemBANCC Project
As with all IMI projects StemBANCC is organised and
funded through a public-private partnership between the Eu-
ropean Union (EU) and the European Federation of Pharma-
ceutical Industries and Associations (Efpia). A key goal of
StemBANCC is to generate a resource of 1,500 well-
characterised induced pluripotent stem cells (iPSC) from 500
participants across a range of disease groups and healthy con-
trols. [14] The consortium is not merely a large-scale collec-
tion project, but is also committed to utilising these iPSC lines
to develop robust cellular models of disease and assay plat-
forms suitable for screening potential new drug candidates. In
order to manage this ambitious task, the StemBANCC con-
sortium incorporates a range of disciplinary expertise across
partners from the pharmaceutical industry, small and medium
enterprises (SMEs), and academic research institutions across
Europe. With 35 partner organisation spread across 10 differ-
ent countries and a budget of 55.6 million Euros over 5 years,
StemBANCC is one of the largest of the 40-plus IMI consortia
established to date.
Intellectual property rights, competition and data protection
laws can all limit access to cell lines. [13] Consortia supported
through the IMI and similar initiatives are specifically de-
signed to overcome these barriers. [15] Partners in a consor-
tium like StemBANCC become legally bound to a shared set
of rules on intellectual property rights, attribution of contribu-
tions to peer-reviewed publications, financial arrangements
between partners, and other terms. The benefits of these agree-
ments are evident when it comes to establishing data gover-
nance structures, as the terms under which data can be shared
and the entitlements of all partner groups to the shared project
material are agreed in advance. The StemBANCC project
agreement specifically states that a ‘Biorepository Materials
and Data Access Committee’ (BMDAC) with responsibility
for ‘transparent and accountable research governance with
regards to use of the samples [the iPSC lines]’ will be
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established and sets a date for the committee to be operational
as a project deliverable.
The agreement also stipulates that the online Stem Cell
Database (StemDb) platform [16] will be used for storing
and sharing clinical, genomic and other project data in
digitised form. All of this data is guaranteed to be accessible
by all consortium partners under the terms of the project
agreement, so in practice governing access to StemDB has
largely involved creating different access rights for those re-
sponsible for uploading and editing data and those who only
need to view it. StemBANCC iPSC lines are also stored in a
central repository, the Human Biomaterials Resource [17]
(HBRC) in Birmingham, UK.Much of the work reported here
focused on creating a governance system to ensure fair and
timely access to this shared material resource for all consor-
tium partners. Implementing a governance structure still re-
quires work because, while IMI terms set out clear rules on
who is entitled to access shared data and materials in collab-
orative consortia, these rules still require interpretation as to
how the specified goals will be achieved in practice.
What is Governance and why is it Needed?
At a general level, governance can be described as ‘the inten-
tional activity of attempting to control, order or influence the
behaviour of others’. [18] Governance is different from regu-
lation in that the latter is limited to maters of formal law and
regulatory bodies with legally defined powers and scope. In-
stead governance encompasses a wider range of formal and
informal methods of co-ordinating and organising activities.
There are a number of advantages to establishing systemic
governance of research. Co-ordinating and organising com-
plex, distributed activities like stem cell research helps create
standardisation and foster efficiency. In terms of agreeing and
implementing standards there are some parallels between the
role the International Stem Cell Initiative plays in co-
ordinating SCR in laboratories at a global level and the func-
tion of a governance framework in an international consor-
tium, albeit with the latter at a smaller scale and for a limited
duration. A governance framework must clearly set out what
must be done, how it should be done, the order in which
procedures should be carried out, and where responsibility lies
for particular tasks. [8] This facilitates transparency – every-
one involved knows what the rules are and that they apply
equally to all partners and accountability, helping to build trust
between partners who may not have previously worked to-
gether. Having a governance framework also defines decision
making roles and provides opportunities for different partners
to have input in a co-ordinated manner1 allowing even large
projects to be responsive to unanticipated issues and to man-
age uncertainty [19].
When developing a governance framework for internal ma-
terials and data sharing within the StemBANCC consortium,
the field of biobanking provides a useful starting point. Extant
biobank governance frameworks include formal regulatory
documents and procedures, such as mandatory licenses and
review from Research Ethics Committees, as well as less for-
mal norms of working with tissue culture, guidelines on best
practice, policy documents, input from leaders in the field and
mechanisms such as project Data Access Committees [8]. The
basic components of the StemBANCC materials and data
sharing framework, such as a Data Access Committee and a
materials and data access policy document, were adopted from
this list. In addition, the development of a specific governance
framework needs to be targeted to the specific task of sharing
materials and data and must be proportionate in making sure
the burden of governance in terms of time and workload does
not outweigh the advantages of having a governance frame-
work. [8] The way in which these principles were enacted in
practice is illustrated in the next section describing the design
and implementation of the StemBANCC materials and data
access framework.
Creating a Materials and Data Access Governance
Structure for StemBANCC
For many participants in a consortium, developing a materials
and data access policy will not be their primary responsibility
and will not have high priority in their list of allocated tasks.
With StemBANCC, a small, dedicated working group was set
up to begin the process of creating a policy document by
translating the terms of the project agreement into an outline
policy. This draft document was then sent out to the represen-
tatives of each consortium partner and leaders of relevant
working groups for feedback and review. This initiated a sec-
ond stage of iterative development, where the policy docu-
ment was revised by the working group and send out again
for further rounds of feedback until a consensus policy docu-
ment acceptable to all consortium partners was arrived at. The
duration of the processes was managed by issuing strict dead-
lines for partners to respond to each new draft of the materials
and data access policy and by using multiple communication
tools, such as emails for routine written comments on a draft
and teleconferences to bring multiple partners together when
an issue required intra-consortium discussion.
Step 1: Translating the Project Agreement to Draft Policy
In order to comply with the terms of the StemBANCC project
agreement, practical governance arrangements needed to en-
sure that i) all partners had equal access to project stem cell
lines and ii) these cell lines could be requested for both the
agreed tasks set out in the agreed description of work (project
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use) and for partners’ own ‘in-house’ research purposes (re-
search use).
This first objective set a clear limit on the scope for action
of the Biorepository Materials and Data Access Committee.
There were no grounds for refusing any partner access to any
StemBANCC iPS cell line so the committee’s role was to
facilitate access in a fair and transparent way, not to decide
who had access and who did not. The BMDAC was therefore
positioned as an intermediary between the physical storage
site for StemBANCC iPSC and the various partner groups
and laboratories across Europe entitled to request these lines.
The role of the committee is to:
& Create a single contact point and a well-defined process
for requesting cell lines, removing this administrative bur-
den from staff at the central repository.
& Design and make available a simple mechanism (a request
form) for all consortium partners to request StemBANCC
cell lines.
& Review cell line request forms sent to the committee. Re-
quests cannot be refused, but if a form is not filled in
correctly or is unclear more information can be requested.
& Retain approved forms to generate an audit trail of which
lines have been requested, by which partners and for
which purposes , providing t ransparency and
accountability.
& Foster transparency and trust by ensuring that industry and
academic partners are equally represented in the BMDAC
membership (along with representatives of the initial
working group and the consortium management).
The latter point was achieved in practice by requiringmem-
bers of the committee to be appointed by nomination, where
each nomination had to be approved by a vote of the consor-
tium’s General Assembly.
The second objective, allowing access for both project and
in-house research raised the question of whether there was any
benefit in establishing a practical difference between project
and research usage. Both uses are legally guaranteed to part-
ners under the project agreement, so it was important that
neither use was subject to any undue restriction. However, a
distinction would allow project work to be prioritized over
research use if at any point a temporary shortage of any given
iPSC line arose at the HBRC. Thus another component of
application process emerged; two levels of access requests
for consortium users – level 1 for project use and level 2 for
research use. This basic governance process for accessing
StemBANCC stem cell lines is illustrated in Fig. 1.
Step 2: Iterative Development
Once the first draft policy document was written, it was then
shared among consortium partners for review and feedback.
This is a practical way of producing inclusivity by allowing all
partners to have their say in producing an important decision
making tool for the consortium. Unsurprisingly a commonly
expressed concern was that increased bureaucracy risked im-
peding the scientific work. To address this, it was decided that
there should be an agreed maximum time period between the
BMDAC receiving a cell line request and either authorising
the release of cell lines from the central repository or
requesting further information. It was further proposed that
this ‘turnaround time’ for cell line requests should be linked
to the level of the request. Level 1 requests would be proc-
essed and a decision communicated to the requestor within a
maximum of three working days while Level 2 requests, being
slightly lower priority, would have a maximum turnaround
time of five working days.
This iterative process for developing a policy allows some
elements of the policy to become agreed at each iteration,
permitting a general outline or skeleton of the proposed gov-
ernance structure to emerge early on, while the finer details of
each major component can be added with subsequent and
more targeted iterations. For example, once a standard cell
line request form was agreed as an appropriate tool, and a
distinction between level 1 and 2 access requests accepted,
the issue of specifically what information needed to be record-
ed about level 1 and 2 requests on the request form could be
discussed. At one point a 300 word description of the intended
research for which each cell line was being requested was
mooted, but rejected on the grounds of being overly time
consuming for requestors. A number of partners also felt that
the requirement of an explicit description of ‘in house’ re-
search projects associated with level 2 requests could compro-
mise the privacy of the non-collaborative parts of their re-
search. Consequently it was agreed that level 1 requests
should list the project task (as set out in the original project
documents) on the cell line request form, whilst level 2 re-
quests would be characterised by selecting one or more ele-
ments from a pre-defined tick-box list, such as ‘pre-clinical
research’ or ‘neuroscience’.
The second part of the development process also brings the
majority of consortium partners into contact with the working
group andwith each other at a relatively early stage in the project.
It is an opportunity for new or unexpected issues or gaps in
existing planning to be uncovered and discussed. Issues that were
raised in the course of the development of the StemBANCC
BMDAC policy included, sharing lines with external partners
later in the project, whether valuable tissue samples and data
from external projects could be incorporated into the project,
and whether, given the research use provisions, partners could
include collaborations with third parties as part of their entitle-
ment to use StemBANCC iPSC for in-house research.
Not every issue needs to be addressed in the context of
discussing the data access policy and some can readily be
moved to other fora within the project. Some are relatively
684 Stem Cell Rev and Rep (2015) 11:681–687
simple to resolve; for example the issue of third party collab-
orations on non-project (level 2) research was addressed by
adding a monitoring section on the cell line request form to
check if level 2 uses involve any planned collaborations and
imposing a requirement on the requesting party to state how
StemBANCC material and IP will be protected in such
instances.
Others are more complex and generate new project tasks
and roles for governance actors. The idea of including ‘exter-
nal’ lines via the standard means of a material transfer agree-
ment (MTA), was deemed to be in direct conflict with the
project’s intention of creating an open resource for European
researchers, as an MTA could allow third parties ‘reach
through rights’ that would limit the free use of on
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Fig. 2 Operational governance framework for cell line access in StemBANCC
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StemBANCC material. However some project partners were
willing to share existing tissue samples with StemBANCC to
be reprogrammed without incorporating any legal claims to
the reprogramedmaterial. This then led to an extra project task
being established for the project’s ethics members in assessing
the informed consent provisions of the external projects
through which these tissue samples were collected and evalu-
ating whether the provisions were adequate to permit the sam-
ples to be incorporated in StemBANCC. It also led to discus-
sion of how these external lines fit into the StemBANCC
governance framework and ultimately resulted in an addition-
al category of ‘rare lines’ being developed.
Rare lines described a small number of tissue samples with
very rare genomic variants which could be shared with
StemBANCC for project use, but where the ethics approval
on the lines meant that the original custodian had to give ex-
plicit and specific permission for each use. In this situation the
standard information provided for level 2 research use requests
was insufficient to allow approval. The procedure developed to
deal with this case was that level 2 requests for rare lines could
be made, but the requestor and line custodian would then agree
to discuss the details of proposed research in confidence before
the custodian would make a final decision. Ultimately, the
StemBANCC Biorepository Materials and Data Access policy
that resulted from this iterative process was unanimously ap-
proved by a vote of the project General Assembly, which in-
cluded voting representatives of all consortium partners. The
operational version of the governance process for accessing
StemBANCC stem cell lines is illustrated in Fig. 2.
Conclusion
The processes and discussions described above cannot claim
to be a complete account of everything that occurred during
the creation of a materials and data access governance frame-
work for StemBANCC. They are necessarily a selection de-
signed to illustrate the type of issues involved in building a
consortium-specific policy. As noted above these exact chal-
lenges are unlikely to recur in exactly the same way in other
SRC consortia. Nonetheless, they do demonstrate the applica-
tion of the key principles of better regulation - consistency,
transparency, accountability, proportionality and targeting [8]
in the practical development of a consortium materials and
data access policy. There are also certain basic commonalities
for all large SCR collaborative consortia. As material objects
stem cells need to be stored at a physical location. Whether
this is a single site for the whole project (as with
StemBANCC) or multiple sites will depend on the needs of
the project. However, there will still need to be a governance
system in place to set out the procedures for accessing lines
and to record the transfer of lines between sites for audit pur-
poses. Aside from enabling transparency and accountability,
there are clear advantages for reproducibility and reliability of
research findings if different groups within a project working
on the same line or lines are all working on samples from the
same storage site, supplied at the same passage number. The
legal agreements underpinning future academic-industry col-
laborations in SCR supported by the IMI and other initiatives
may change but they will still require translation into practical
arrangements of policy documents and procedures.
In this, the overall techniques applied in the creation of the
StemBANCC BMDA policy are relevant to other current or
future consortia. The use of a small working group to translate
the requirements of a consortium agreement into a draft docu-
ment for a governance structure is a practical solution to the
problem that a general request for early input on data sharing
policy is likely to result in vague or very general recommenda-
tions or a laissez-faire approach. At the same time, collabora-
tions are inherently relational – they can only succeed if the
different groups involved can agree to work in concert. A
shared goal is an important unifying factor, but it needs to be
complemented by internal mechanisms that generate interac-
tion between partners. In governance terms this means taking a
network approach to developing group documents and proce-
dures rather than a top-down hierarchical approach, hence the
second, iterative phase of policy development that allows all
partners to be equally involved. This helps to build trust, which
is especially important when partners are geographically sepa-
rated, come from different institutional cultures and have dif-
ferent sets of expertise. It also has the merit that partners are
more likely to feel a joint ownership in the final policy docu-
ment as something built up collaboratively rather than seeing it
as something imposed through ‘top-down’ project structures.
Finally, using an iterative discussion component also acts
as an exploratory space where different options can be pro-
posed, potential gaps in planning brought up, and compro-
mises negotiated. This can be seen as a challenge for project
management and organisation, but it also has a number of
potential benefits that are worth considering beyond the
StemBANCC case. Having a space for open discussion can
bring to light issues and concerns of different partners that
might otherwise not have found expression elsewhere and
provides an opportunity for discussion and resolution of these
issues prior to any disagreement that might arise at a more
critical juncture in a project. Of course, such a potentially
open-ended process requires careful time management strate-
gies. Within StemBANCC an overall timeframe was set in
advance by having an active BMDAC as a specified project
deliverable with a fixed delivery date. Proportionality - ensur-
ing the burden of a particular governance mechanism, in terms
of time, effort and workload involved, does not outweigh its
advantages and targeting - making sure the governance struc-
ture stays focused only on the issues it was designed to address
and does not grow too broad and unwieldy are also important
in keeping the process on track. Examples in creating the
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StemBANCC BMDA policy include implementing a 3 days
turnaround time for the BMDAC to review requests for cell
lines, balancing the desire to audit level 1 and 2 requests with
the time costs and privacy concerns of consortium partners,
and making sure that issues such as future costs were moved
out of the materials and data access policy discussion and into
other fora within the consortium. Ultimately, the arrangements
reached in StemBANCC do not necessarily exemplify a
universalisable best practice; but they do represent a model
for making the best decisions for sharing materials and data
within a particular SCR consortium at a given time, and based
on the information available.
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